BOHLIN GAREN G 4

What Happened
Garen G. Bohlin, a director of Karyopharm Therapeutics Inc. (KPTI), was granted 15,508 restricted stock units (RSUs) on May 21, 2026. The RSUs were reported at $0.00 per share (award/grant, transaction code A) — no cash was exchanged. The RSUs convert one-for-one into common shares, vesting 100% on May 21, 2027, but actual delivery of shares is deferred until the earlier of the director’s separation from service or a change‑in‑control event.

Key Details

• Transaction date: May 21, 2026; Form 4 filed May 26, 2026 (filed within the SEC two-business-day window given the Memorial Day holiday).
• Grant: 15,508 RSUs; reported price $0.00; total cash value on grant not reported.
• Shares owned after transaction: not specified in the filing.
• Footnotes: F1 — RSUs granted under Karyopharm’s 2022 Equity Incentive Plan; F2 — reported amounts reflect a one-for-fifteen reverse stock split effective Feb 25, 2025.
• Transaction type: Award/Grant (A) — part of director compensation, not an open-market buy or sale.

Context
RSU awards to directors are common as compensation and do not represent an open‑market purchase (a stronger bullish signal) or a sale. These RSUs vest fully one year from the grant date but are subject to deferred delivery until separation or a change‑in‑control, so they may not result in immediate share issuance. The filing appears timely under SEC rules.